Phil Beales

Company: Axovia Therapeutics

Job title: CEO

Seminars:

De-risking Translation in Rare Ophthalmic Gene Therapy: The Axovia Experience 2:30 pm

Leveraging a disease-specific animal model, single-species toxicology, and dose-ranging studies to assess tolerability and efficacy Navigating an adaptable regulatory pathway, pivoting from US to UK-based Phase 1 trials, with a registrational trajectory toward BLA submission Driving patient access through close PAG engagement and optimizing recruitment strategiesRead more

day: Conference Day One